Abstract
Background: The treatment of patients with metastatic synovial sarcoma is still challenging, and the development of new molecular therapeutics is desirable. Dysregulation of Wnt signaling has been implicated in synovial sarcoma. Traf2-and-Nck-interacting kinase (TNIK) is an essential transcriptional co-regulator of Wnt target genes. We examined the efficacy of a small interfering RNA (siRNA) to TNIK and a small-molecule TNIK inhibitor, NCB-0846, for synovial sarcoma. Methods: The expression of TNIK was determined in 20 clinical samples of synovial sarcoma. The efficacy of NCB-0846 was evaluated in four synovial sarcoma cell lines and a mouse xenograft model. Results: We found that synovial sarcoma cell lines with Wnt activation were highly dependent upon the expression of TNIK for proliferation and survival. NCB-0846 induced apoptotic cell death in synovial sarcoma cells through blocking of Wnt target genes including MYC, and oral administration of NCB-846 induced regression of xenografts established by inoculation of synovial sarcoma cells. Discussion: It has become evident that activation of Wnt signaling is causatively involved in the pathogenesis of synovial sarcoma, but no molecular therapeutics targeting the pathway have been approved. This study revealed for the first time the therapeutic potential of TNIK inhibition in synovial sarcoma.
Highlights
Synovial sarcoma is a rare aggressive neoplasm that accounts for 10–20% of soft tissue sarcomas.It affects mainly adolescents and young adults [1,2], and 40–50% of patients are under the age of 30 at diagnosis [3]
We found that Traf2-and-Nck-interacting kinase (TNIK) was essential for transactivation of Wnt target genes and that colorectal cancer cells were highly sensitive to TNIK inhibition [19,20]
The four synovial sarcoma cell lines were transfected with small interfering RNA (siRNA) to TNIK or control siRNA, and their viability was assessed 72 h later
Summary
It has become evident that activation of Wnt signaling is causatively involved in the pathogenesis of synovial sarcoma, but no molecular therapeutics targeting the pathway have been approved. This study revealed for the first time the therapeutic potential of TNIK inhibition in synovial sarcoma
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have